Pilulka Lekarny AS (XPRA:PINK) EBIT: Kč0 Mil (TTM As of Dec. 2025)


XPRA:PINK Pilulka Lekarny AS XPRA:PINK
49 GF Score
Price Kč115.00
GF Value Kč114.69
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is Pilulka Lekarny AS EBIT?

Pilulka Lekarny AS XPRA:PINK -4.17% 49 EBIT is Kč0 Mil as of Dec. 2025. GuruFocus rates XPRA:PINK with a GF Score™ of 49/100 and a GF Value™ of Kč114.69 (Fairly Valued). The stock has 6 warning signs investors should review.

Pilulka Lekarny AS's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2025 was Kč0 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was Kč0 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Pilulka Lekarny AS's annualized ROC % for the quarter that ended in Dec. 2025 was 0.00%. Pilulka Lekarny AS's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 0.00%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Pilulka Lekarny AS's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 0.00%.

Pilulka Lekarny AS  (XPRA:PINK) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Pilulka Lekarny AS's annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

ROC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2024 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=0 * ( 1 - % )/( (236.45 + 124.023)/ 2 )
=0/180.2365
=0.00 %

where

Invested Capital(Q: Dec. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=237.335 - 181.718 - ( 10.171 - max(0, 326.954 - 146.121+10.171))
=236.45

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=197.146 - 156.638 - ( 15.642 - max(0, 227.235 - 143.72+15.642))
=124.023

Note: The Operating Income data used here is two times the semi-annual (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

Pilulka Lekarny AS's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2024  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=0/( ( (21.137 + max(-154.646, 0)) + (9.005 + max(-60.117, 0)) )/ 2 )
=0/( ( 21.137 + 9.005 )/ 2 )
=0/15.071
=0.00 %

where Working Capital is:

Working Capital(Q: Dec. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(67.449 + 54.739 + 4.071) - (181.718 + 0 + 99.187)
=-154.646

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(39.332 + 63.375 + 10.312) - (156.638 + 0 + 16.498)
=-60.117

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Pilulka Lekarny AS's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2025 )
=0/346.866
=0.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pilulka Lekarny AS EBIT Related Terms

Pilulka Lekarny AS EBIT Historical Data

* Premium members only.

The historical data trend for Pilulka Lekarny AS's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pilulka Lekarny AS EBIT Chart

Pilulka Lekarny AS Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial -23.90 -59.25 -165.39 -114.04 -21.53

Pilulka Lekarny AS Semi-Annual Data
Dec20 Dec21 Dec22 Dec23 Jun24 Dec24 Dec25
EBIT Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Pilulka Lekarny AS EBIT Competitor Comparison

For the Pharmaceutical Retailers subindustry, Pilulka Lekarny AS's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pilulka Lekarny AS EV-to-EBIT vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Pilulka Lekarny AS's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Pilulka Lekarny AS's EV-to-EBIT falls into.


XPRA:PINK
49GF Score
Pilulka Lekarny AS XPRA:PINK
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pilulka Lekarny AS EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was Kč0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of Kč0 Mil mean?
Pilulka Lekarny AS (XPRA:PINK) has a EBIT of Kč0 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Pilulka Lekarny AS.
Is Pilulka Lekarny AS's EBIT too high?
Pilulka Lekarny AS's current EBIT is Kč0 Mil. Overall, Pilulka Lekarny AS has a GF Score™ of 49/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Pilulka Lekarny AS's EBIT compare to competitors?
Pilulka Lekarny AS's EBIT of Kč0 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Healthcare Providers & Services company?
A good EBIT depends on the Healthcare Providers & Services industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Pilulka Lekarny AS. Pilulka Lekarny AS's current EBIT is Kč0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pilulka Lekarny AS stock overvalued right now?
Based on GuruFocus' analysis, Pilulka Lekarny AS (XPRA:PINK) is currently considered Fairly Valued. The stock's GF Value™ is Kč114.69, compared to a current price of Kč115.00 — trading 0.3% above its estimated fair value. The current EBIT is Kč0 Mil. Pilulka Lekarny AS's overall GF Score™ is 49/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Pilulka Lekarny AS (XPRA:PINK), the current EBIT is Kč0 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pilulka Lekarny AS (XPRA:PINK) Overvalued in 2026?

Based on GuruFocus' analysis, Pilulka Lekarny AS stock appears to be overvalued. The current stock price of Kč115.00 is trading 0.3% above its estimated GF Value™ of Kč114.69. GuruFocus considers Pilulka Lekarny AS to be Fairly Valued.

Key valuation signals for XPRA:PINK:

  • EBIT: Kč0 Mil
  • GF Value™: Kč114.69 vs. price of Kč115.00 (0.3% above fair value)
  • GF Score™: 49/100 with 6 warning signs

No single metric tells the full story. See the XPRA:PINK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Pilulka Lekarny AS Business Description

Address Drahobejlova 1073/36, Prague, CZE, 190 00
Pilulka Lekarny AS operates an online pharmaceutical store by distribution of medicinal products. The store offers over-the-counter-drugs, dietary supplements, baby foods, mother care products, cosmetics, other prescription drugs, sport nutritional products, diagnostic test kits, orthopaedic supplies, first aid kits, and other related products.
49GF Score

Get the complete analysis for XPRA:PINK

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

Kč115.00
Price
Kč114.69
GF Value